Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst Inc. is expected to maintain high single-digit organic growth as it expands its client base and implements contractual price escalators, targeting long-term margin expansion towards 20%. The company reported better-than-anticipated fourth-quarter results, supported by improvements in the Ignite platform and prospects for increased profitability. Additionally, the integration of both technology and professional services positions Health Catalyst favorably in the market, as evidenced by the signing of 32 new platform customers, which surpassed revised expectations, suggesting potential for future value creation for shareholders.

Bears say

Health Catalyst's stock faces a negative outlook primarily due to projected revenue declines and disappointing guidance for the upcoming quarters, with an expected organic revenue decrease of 2-3% for Q4 and a y/y decline ranging from 11.9% to 14.3% in Q1 2026, which is below consensus estimates. The transition towards the lower-cost Ignite platform has resulted in down-selling and potential customer attrition, exacerbated by economic uncertainties impacting the healthcare purchasing environment. Additionally, while the company is undertaking restructuring to mitigate some losses, the overall forecast for 2026 indicates further revenue reductions, contributing to concerns about future growth and profitability.

HCAT has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 9 analysts, HCAT has a Hold consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.97, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.97, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.